Thiotepa in the Treatment of Tumours of the Bladder

Jones, H.C.; Swinney, John

doi:10.1016/s0140-6736(61)90304-x

Cited by 205 publications

(34 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For systemic chemotherapy the reader is referred to our previous articles about this topic \Pavone-Macaluso, 1971, 1978aPavone-Macaluso and EORTC Urological Group, 1976]. 18 years have elapsed since the reports by Jones and Swinney [1961] and by Veenema et al [1962] about topical chemotherapy of bladder tu mours with thiotepa, which marked the beginning of modern intravesical treatment with chemotherapeutic agents. After thiotepa, other compounds have been employed with variable success.…”

mentioning

confidence: 99%

Local Chemotherapy in Bladder Cancer Treatment

Pavone‐Macaluso¹,

Ingargiola²

1980

Oncology

View full text Add to dashboard Cite

Intravesical chemotherapy can be employed either in a therapeutic aim or as an adjuvant prophylactic treatment after TUR. In this paper a discussion is presented about various controversial points that need to be clarified with regard to topical chemotherapy, with special reference to the selection of the drug and to various modalities of treatment. Some results are presented from the literature and from the author’s personal experience, with emphasis on the randomized clinical trials performed by EORTC and by other workers or groups.

show abstract

mentioning

confidence: 99%

Local Chemotherapy in Bladder Cancer Treatment

Pavone‐Macaluso¹,

Ingargiola²

1980

Oncology

View full text Add to dashboard Cite

show abstract

“…One-third of his patients had complete tumor disappearance, one-third had partial regression and the remaining third had no effect. Since his report this polyfunctional alkylating agent has been widely used for topical chemotherapy of bladder carcinoma and general agreement with the clinical usefulness of Thio Tepa is established (Jones and Swinney 1961;Wescott 1966;Veenema et al 1969). …”

mentioning

confidence: 73%

Cidal and subcidal effect of triethylene thiophosphoramide on cell kinetics of human bladder carcinoma cells in vitro.

Kato

Irwin

1977

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

“…Jones and Swinney [7] described in 1961 the use of intravesical thiotepa which was later the first intravesical drug FDA approved for NMIBC; however, its side effect rates were high, so it was not commonly used.…”

Section: Historical Reviewmentioning

confidence: 99%

Intravesical Chemohyperthermia for NMIBC: Rationale and Results of This Developing Treatment

Alejandro¹,

Javier²,

Daniel³

et al. 2017

Bladder Cancer - Management of NMI and Muscle-Invasive Cancer

View full text Add to dashboard Cite

Bladder cancer is the fourth most common cancer in men, and the lifetime risk of getting bladder cancer is 2.4%. Approximately 75% of newly diagnosed cases of bladder cancer are non-muscle-invasive bladder cancer (NMIBC), and half of them will show recurrence and/or progression after transurethral resection. Therefore, after transurethral resection, in high-risk patients, intravesical therapy is mandatory. However, bacillus CalmetteGuérin (BCG) is associated with important side effects such as systemic tuberculosis and bladder retraction. Chemohyperthermia (CHT) has shown a 60% lower recurrence rate than standard mitomycin C (MMC). However, its effectiveness in high-risk patients, especially CIS and BCG refractory patients, is even more important. CHT will probably be an option for patients unsuitable for radical cystectomy or those on whom BCG can't be used. Two main technologies are currently available for intravesical CHT: microwaves and recirculating heated fluids. Both of them have pros and cons that should be known and evaluated by a urologist. In this chapter, we will speak about rationale, technical options, clinical results, ongoing studies, and future perspective for this interesting treatment option for intermediate and high-risk patients with NMIBC.Keywords: NMIBC, MMC, BCG, chemohyperthermia, radio frequency, recirculant systems, adjuvant, neoadjuvant BackgroundIn 2002, the world-adjusted incidence rate of bladder cancer was 33 new cases/100,000 inhabitants/year. That makes it the fourth tumor with the highest incidence in men, after lung, prostate, and colorectal cancers [1].© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Each body tumor has unique characteristics in terms of its presentation, histological types, surgical approaches, and sensitivity to different types of treatment (surgery, chemotherapy,Approximately, 95% of bladder neoplasms are urothelial carcinomas, and 75% of them will be diagnosed as non-muscle-invasive tumors. However, they have a high tendency to recur, and one-third of them will reappear during the first 5 years after transurethral resection. Incidence of recurrence and progression is directly related to the tumoral grade and stage, being higher in carcinoma in situ and T1G3 tumors.Most recidives have similar grade and stage to the original tumor. However, a significant number of bladder cancers progress to invasive tumors whose prognosis and treatment are completely different. Therefore, intravesical postoperative therapy is mandatory, especially in those with medium and high-risk tumors.The urethra allows ease of access from the outside, which generally allows a resection of the tumor and the application of chemo-and/or immunotherapy locally with minimal systemic toxicity.Intravesical chemotherapy, with single postoperat...

show abstract

Thiotepa in the Treatment of Tumours of the Bladder

Cited by 205 publications

References 3 publications

Local Chemotherapy in Bladder Cancer Treatment

Local Chemotherapy in Bladder Cancer Treatment

Cidal and subcidal effect of triethylene thiophosphoramide on cell kinetics of human bladder carcinoma cells in vitro.

Intravesical Chemohyperthermia for NMIBC: Rationale and Results of This Developing Treatment

Contact Info

Product

Resources

About